Bridgewater, NJ, United States of America

Vyne Therapeutics Inc.


USPTO Granted Patents = 6

% Expired Patents = 50.0

Trademarks = 9

Forward Citations = 13

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Dov Tamarkin (5 out of 104 patents)

silverMedal David Schuz (5 out of 57 patents)

bronzeMedal Rita Keynan (4 out of 32 patents)

4.  Tal Berman (3 out of 23 patents)

5.  Elana Gazal (3 out of 29 patents)

6.  Yohan Hazot (2 out of 37 patents)

7.  Enbal Ziv (2 out of 15 patents)

8.  Irakliy Papiashvili (2 out of 21 patents)

9.  Xiaoming Zhang (1 out of 68 patents)

10.  Helena Shifrin (1 out of 12 patents)

11.  Doron Friedman (1 out of 72 patents)

12.  Edward F Schnipper (1 out of 16 patents)

13.  Andrew J Perlman (1 out of 14 patents)

14.  James W Larrick (1 out of 56 patents)


6 patents:

Company Overview
Vyne Therapeutics Inc. is a biotechnology company focused on developing innovative gene therapies for rare and genetic diseases. The company leverages cutting-edge gene editing technology to deliver transformative treatments to patients in need. With a strong commitment to research and development, Vyne Therapeutics is dedicated to advancing the field of gene therapy and improving the lives of patients worldwide.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Vyne Therapeutics Inc. USPTO Patent Assignee Logo
6 Patents

#37 in Bridgewater, NJ

#1,675 in New Jersey

#44,981 in US

Bridgewater, NJ (US)
Bridgewater, NJ, United States of America
Forward Citations = 13

14 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vyne Therapeutics Inc.. Retrieved from https://idiyas.com/company/vyne-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…